Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
City of Dreadful Delight: Narratives of Sexual Danger in Late-Victorian London
- C. Morgan, Judith R. Walkowitz
- Sociology
- 1993
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
- G. Churchyard, C. Morgan, +24 authors M. Keefer
- Biology, Medicine
- PloS one
- 3 August 2011
Background The safety and immunogenicity of a vaccine regimen consisting of a 6-plasmid HIV-1 DNA prime (envA, envB, envC, gagB, polB, nefB) boosted by a recombinant adenovirus serotype-5 (rAd5)… Expand
The Use of Nonhuman Primate Models in HIV Vaccine Development
- C. Morgan, M. Marthas, +14 authors L. Corey
- Biology, Medicine
- PLoS medicine
- 1 August 2008
Cecilia Morgan and colleagues outline a two-stage nonhuman primate screening strategy for T cell-based HIV-1 vaccines.
Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived…
- Kylie M. Quinn, A. Da Costa, +23 authors R. Seder
- Biology, Medicine
- The Journal of Immunology
- 15 March 2013
Recombinant adenoviral vectors (rAds) are the most potent recombinant vaccines for eliciting CD8+ T cell–mediated immunity in humans; however, prior exposure from natural adenoviral infection can… Expand
DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
- N. Rouphael, C. Morgan, +20 authors M. Keefer
- Medicine
- The Journal of clinical investigation
- 30 September 2019
BACKGROUND RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized,… Expand
Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies
- Wilton B Williams, H. Liao, +43 authors B. Haynes
- Biology, Medicine
- Science
- 14 August 2015
Microbiota can mislead antibodies Unlike the response to many viral infections, most people do not produce antibodies capable of clearing HIV-1. Non-neutralizing antibodies that target HIV-1's… Expand
Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.
Plasmid DNA vaccines have been licensed for use in domesticated animals because of their excellent immunogenicity, but none have yet been licensed for use in humans. Here we report a retrospective… Expand
Feasibility of Identifying a Cohort of US Women at High Risk for HIV Infection for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 906
- B. Koblin, B. Metch, +8 authors I. Frank
- Medicine
- Journal of acquired immune deficiency syndromes
- 1 June 2013
Background:Identifying cohorts of US women with HIV infection rates sufficient for inclusion in vaccine efficacy trials has been challenging. Using geography and sexual network characteristics to… Expand
Public Men and Virtuous Women: The Gendered Languages of Religion and Politics in Upper Canada, 1791-1850
- C. Morgan
- Sociology
- 1 December 1996
Public Men and Virtuous Women: The Gendered Language of Religion and Politics in Upper Canada, 1791-1850. Cecilia Morgan. Toronto: University of Toronto Press, 1996.The primary aim of the University… Expand